Anticoagulation After Mitral Valve Replacement

Mechanical Mitral Valve Replacement

Lifelong warfarin therapy targeting an INR of 3.0 (acceptable range 2.5‑3.5) is mandatory for all patients with a mechanical mitral valve. This is a Class I recommendation with Level B evidence from the American Heart Association. 1
Add low‑dose aspirin (75‑100 mg daily) to warfarin in patients who have a low bleeding risk (no prior gastrointestinal bleeding or other bleeding risk factors). Class I, Level B (American Heart Association). 1
Direct oral anticoagulants (e.g., dabigatran, rivaroxaban, apixaban) are contraindicated for mechanical mitral valves. Class I, Level B (American Heart Association). 1
Initiation protocol:
- Begin postoperative heparin infusion 6 hours after surgery and continue during the hospital stay.
- Start warfarin at 2‑5 mg daily, adjusting dose to INR.
- Target INR 2.5 (range 2.0‑3.0) for the first 3 months, then increase to INR 3.0 (range 2.5‑3.5) thereafter. (Class I, Level B – American College of Cardiology) 2

Warfarin targeting an INR of 2.5 (range 2.0‑3.0) is recommended for at least 3 months and up to 6 months in patients with low bleeding risk. Class IIa, Level B (American College of Cardiology). [3][2]
Stroke risk is highest during the first 90‑180 days after implantation, with an observed 30‑day stroke rate of ≈1.5 %. (American College of Cardiology). [3][4]
Warfarin during this early period reduces annual thrombo‑embolism from 3.9 % to 2.5 %. Class IIa, Level B (American College of Cardiology). 2
Extended warfarin therapy to 6 months (versus stopping at 3 months) was associated with lower stroke and mortality rates without a rise in major bleeding in a Danish registry. (American College of Cardiology). [3][2]

Switch to aspirin alone (75‑100 mg daily) if the patient meets all of the following:
- Sinus rhythm (no atrial fibrillation)
- Left‑ventricular ejection fraction > 30 % (European Society of Cardiology) 5
- No prior thrombo‑embolism (Stroke journal) 6
- No hyper‑coagulable condition (Stroke journal) 6
Continue warfarin indefinitely (INR 2.0‑3.0) plus aspirin (75‑100 mg daily) if any of the following risk factors are present:
- Atrial fibrillation (paroxysmal or persistent)
- Prior thrombo‑embolism (Stroke journal) 6
- Left‑ventricular ejection fraction < 30 % (European Society of Cardiology) 5
- Hyper‑coagulable state (Stroke journal) 6
- Heart failure (European Society of Cardiology) 5

For INR > 6.0, reversal is required but intravenous vitamin K should be avoided because rapid INR reduction can precipitate valve thrombosis. (European Society of Cardiology). 5
INR 6.0‑10.0: Admit the patient, hold warfarin, and allow a gradual decline in INR. (European Society of Cardiology). 5
Life‑threatening bleeding with markedly elevated INR: Administer prothrombin‑complex concentrate (PCC) rather than fresh‑frozen plasma. (European Society of Cardiology). 5

Baseline transthoracic echocardiography should be performed post‑operatively for all valve‑replacement patients. (European Society of Cardiology). 5
Patients with bioprosthetic valves who are not on anticoagulation require close outpatient surveillance for new‑onset atrial fibrillation. (European Society of Cardiology). 5

Current guidelines (European Society of Cardiology) recommend three months of warfarin anticoagulation after mitral valve repair that involves a prosthetic annuloplasty ring. (European Society of Cardiology). 5
Warfarin for three months remains the standard of care until randomized trials demonstrate that omission is safe, despite conflicting observational data. (European Society of Cardiology). 5

The American College of Cardiology recommends warfarin targeting INR 3.0 (range 2.5-3.5) indefinitely for mechanical mitral valves, and INR 2.5 (range 2.0-3.0) for mechanical aortic valves 7, 8
For mechanical mitral valves, the higher INR target compared to aortic valves reflects the substantially greater thrombotic risk in the mitral position 7
Adding aspirin 75-100 mg daily to warfarin is recommended for patients at low bleeding risk (no history of GI bleeding or other bleeding risk factors) with mechanical valves 7
The American Heart Association recommends warfarin targeting INR 2.5 (range 2.0-3.0) for bileaflet mechanical valves (St. Jude Medical) and Medtronic Hall prostheses in the aortic position 7, 9
For On-X aortic valves, after 3 months of standard anticoagulation, a lower INR target of 1.5-2.0 (with aspirin 81 mg daily) may be considered 8

The American College of Cardiology recommends warfarin targeting INR 2.5 (range 2.0-3.0) for at least 3 months and up to 6 months for both mitral and aortic bioprosthetic valves in patients at low bleeding risk 8, 10
For bioprosthetic valves, the early period carries substantially elevated stroke risk, justifying aggressive initial anticoagulation 8
Transition to aspirin 75-100 mg daily alone is recommended for patients without additional risk factors after 3-6 months 10
The American Heart Association recommends continuing warfarin indefinitely (INR 2.0-3.0) plus aspirin 75-100 mg daily if any of the following risk factors exist: previous thromboembolism, left ventricular dysfunction, hypercoagulable state, or enlarged left atrium 10, 11

For transcatheter aortic valve replacement (TAVR), aspirin 50-100 mg plus clopidogrel 75 mg daily for 3 months may be reasonable, though warfarin INR 2.5 for 3 months is also reasonable in low bleeding risk patients 7, 8
Valve thrombosis can occur in bioprosthetic valves and may be warfarin-responsive, supporting the rationale for early anticoagulation 8
The American College of Cardiology states that DOACs have not been adequately studied for bioprosthetic valves and are not recommended 10